Article Sidebar

Submitted
Mar 31, 2026
Accepted
Apr 14, 2026
Published
Apr 23, 2026
Download
pdf
Statistic
Read Counter : 30 Download : 14

Downloads

Download data is not yet available.

Main Article Content

Abstract

 This study aimed to evaluate quinoline-spiro derivatives as potential inhibitors of P. falciparum lactate dehydrogenase (PfLDH), a key enzyme involved in parasite energy metabolism, using an in silico approach. Molecular docking was performed to assess ligand-protein interactions, followed by drug-likeness evaluation based on Lipinski's Rule of Five and pharmacokinetic-toxicity prediction using ADMET analysis. The results showed that all tested compounds exhibited favorable binding interactions with PfLDH, thus demonstrating potential as enzyme inhibitors. Several compounds exhibited stronger binding affinity than reference ligands, suggesting that structural modifications with the spiro framework enhance interaction with the target protein. Most compounds also met drug-likeness criteria, although there were minor deviations. Among the compounds evaluated, one candidate, (Z)-2-((2-(7- chloroquinolin-4 -yl) hydrazinyl) methyl) -4-(3- methylbenzylidene)-2-azaspiro[4.5] decan-3-one showed the most balanced profile, based on results obtained by combining strong binding interactions with favorable pharmacokinetic properties and predicted low toxicity. Quinoline-spiro derivatives may be promising candidates for the development of antimalarial drugs targeting PfLDH. This study describes the integrated in silico evaluation of quinoline-spiro derivatives as PfLDH inhibitors, as drug candidates for further development.

Keywords

quinoline malaria PfLDH molecular docking

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
1.
Rijas LP, Zainul R, Meksim Rebezov, Vikash Jakhmola, Tarek Elkhooly. In Silico Evaluation of Quinoline Derivatives as PfLDH Inhibitors through Molecular Docking, Lipinski’s Rule, and ADMET Profiling . EKSAKTA [Internet]. 2026 Apr. 23 [cited 2026 Apr. 29];27(02):167-81. Available from: https://eksakta.ppj.unp.ac.id/index.php/eksakta/article/view/669

References

  1. Nicolas, M., Josephine, K., Masamba, P., Blessing, M., Simelane, C., & Paul, A. (2025). Understanding the interplay of malarial pathogenesis, host immune response and oxidative stress: Implications for disease progression and therapeutic strategies. Aspects of Molecular Medicine, 5, Article 100082.
  2. [2] Weiss, D., Dzianach, P., Saddler, A., Lubinda, J., Browne, A., McPhail, M., Rumisha, S., Sanna, F., Gelaw, Y., Kiss, J., Hafsia, S., Jayaseelen, R., Baggen, H., Amratia, P., Bertozzi-Villa, A., Nesbit, O., Whisnant, J., Battle, K., Nguyen, M., Alene, K., Cameron, E., Penny, M., Bhatt, S., Smith, D., Symons, T., Mosser, J., Murray, C., Hay, S., & Gething, P. (2025). Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000–22: A spatial and temporal modelling study. The Lancet, 405, 979–990.
  3. [3] Shi, D., Wei, L., Liang, H., Yan, D., Zhang, J., & Wang, Z. (2023). Trends of the global, regional and national incidence, mortality, and disability-adjusted life years of malaria, 1990–2019: An analysis of the Global Burden of Disease Study 2019. Risk Management and Healthcare Policy, 16, 1187–1201.
  4. [4] Ameyaw, K., et al. (2024). Hydroethanol extract and triterpenoids of Senegalia ataxacantha show antiplasmodial activity and the compounds are predicted to inhibit parasite lactate dehydrogenase (pfLDH) as indicated by molecular docking studies. Scientific African, 26, Article e02455.
  5. [5] Opoku, F., Govender, P. P., Pooe, O. J., & Simelane, M. B. (2019). Evaluating iso-mukaadial acetate and ursolic acid acetate as Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase inhibitors. Biomolecules, 9(12), 861.
  6. [6] Fitri, L., Pawestri, A., Winaris, N., Endharti, A., Khotimah, A., Abidah, H., & Huwae, J. (2023). Antimalarial drug resistance: A brief history of its spread in Indonesia. Drug Design, Development and Therapy, 17, 1995–2010.
  7. [7] Eissa, S. I., et al. (2021). Novel structural hybrids of quinoline and thiazole moieties: Synthesis and evaluation of antibacterial and antifungal activities with molecular modeling studies. Bioorganic Chemistry, 110, Article 104803.
  8. [8] Chavan, N. D., Sarveswari, S., & Vijayakumar, V. (2025). Quinoline derivatives' biological interest for anti-malarial and anti-cancer activities: An overview. RSC Advances, 15(37), 30576–30604.
  9. [9] Ibrahim, M. A., & Badran, A. (2020). Synthesis and chemical reactivity of novel pyrano[3,2-c]quinoline-3-carbonitriles. Synthetic Communications, 1–12.
  10. [10] Naik, M. D., Bodke, Y. D., & Naik, J. K. (2021). An efficient multicomponent synthesis of 1H-pyrano[2,3-d]pyrimidine-2,4(3H,5H)-dione derivatives and evaluation of their α-amylase and α-glucosidase inhibitory activity. Journal of Chemical Research, 45(3–4), 228–236.
  11. [11] Sama-Ae, I., Muengthongon, P., Tohlaeh, A., Rukhachan, W., Kiattikul, P., Samaeng, F., Mitklin, A., Rahman, M., Tedasen, A., Kwankaew, P., Kotepui, M., & Kepan, A. (2025). Penicillium-derived inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH): A computational approach for novel antimalarial therapy development. Scientifica, 2025.
  12. [12] Heikal, M., Putra, W., S., Rifa’i, M., Hidayatullah, A., Ningsih, F., Widiastuti, D., Shuib, A., Zulfiani, B., & Hanasepti, A. (2023). In silico screening and molecular dynamics simulation of potential anti-malarial agents from Zingiberaceae as potential Plasmodium falciparum lactate dehydrogenase (PfLDH) enzyme inhibitors. Tropical Life Sciences Research, 34, 1–20.
  13. [13] Akinnusi, P. A., Olubode, S. O., Adebesin, A. O., Osadipe, T. J., Nwankwo, D. O., Adebisi, A. D., ... & Oyebola, K. M. (2023). Structure-based scoring of anthocyanins and molecular modeling of PfLDH, PfDHODH, and PfDHFR reveal novel potential P. falciparum inhibitors. Informatics in Medicine Unlocked, 38, 101206.
  14. [14] Kreutzfeld, O., Tumwebaze, P., Okitwi, M., Orena, S., Byaruhanga, O., Katairo, T., Conrad, M., Rasmussen, S., Legac, J., Aydemir, O., Giesbrecht, D., Forte, B., Campbell, P., Smith, A., Kano, H., Nsobya, S., Blasco, B., Duffey, M., Bailey, J., Cooper, R., & Rosenthal, P. (2023). Susceptibility of Ugandan Plasmodium falciparum isolates to the antimalarial drug pipeline. Microbiology Spectrum, 11.
  15. [15] Berdigaliyev, N., & Aljofan, M. (2020). An overview of drug discovery and development. Future Medicinal Chemistry, 12(10), 939–947.
  16. [16] Pinzi, L., & Rastelli, G. (2019). Molecular docking: Shifting paradigms in drug discovery. International Journal of Molecular Sciences, 20(18).
  17. [17] Sharma, B., Agarwal, A., & Awasthi, S. K. (2023). Is structural hybridization invoking new dimensions for antimalarial drug discovery. MedChemComm, 14, 1227–1253.
  18. [18] Rasyid, H., Idham, M., Mardjan, D., Firdaus, M., & Asmi, N. (2026). In silico design of isoindolinone-hydrazide hybrid compounds as antiplasmodium through molecular docking, molecular dynamics simulation, and MM-PBSA calculation. Chemical Physics Impact, 12, Article 100990.
  19. [19] Patel, N. B., et al. (2026). Quinoline-linked spirocycles as potential antimalarial agents: Design, synthesis, and computational investigations using molecular mechanics and quantum studies. Journal of Molecular Structure, 1349(P2), Article 143698.
  20. [20] Cheema, Y., Linton, K. J., & Jabeen, I. (2024). Molecular modeling studies to probe the binding hypothesis of novel lead compounds against multidrug resistance protein ABCB1. Biomolecules, 14(1), 114.
  21. [21] Weni, M., Safithri, M., & Seno, D. S. H. (2020). Molecular docking of active compounds Piper crocatum on the A-glucosidase enzyme as antidiabetic. Indonesian Journal of Pharmaceutical Science and Technology, 7(2), 64.
  22. [22] Fakih, T. M., Zainul, R., & Muchtaridi, M. (2024). Molecular docking-based virtual screening and computational investigations of biomolecules (curcumin analogs) as potential lead inhibitors for SARS-CoV-2 papain-like protease. Pharmacia, 1–19.
  23. [23] Elfita, L., Apriadi, A., Supandi, & Dianmurdedi, S. (2022). Studi penambatan molekuler dan simulasi dinamika molekuler senyawa turunan furanokumarin terhadap reseptor estrogen alfa (ER-α) sebagai anti kanker payudara. Jurnal Sains Farmasi Klinis, 9, 255–264.
  24. [24] Zainul, R., Novel, D. S., Satriawan, H., Jakhmola, V., Rebezov, M., Suwarni, S., ... & Faridah, A. (2024). In silico gene transcription of 4-hydroxycinnamic acid from broccoli fruit (Brassica oleracea var. italica) with estrogen receptor beta protein. Pharmacognosy Journal, 16(4).
  25. [25] Mateev, E., Valkova, I., Angelov, B., Georgieva, M., & Zlatkov, A. (2022). Validation through re-docking, cross-docking and ligand enrichment in various well-resoluted MAO-B receptors. International Journal of Pharmaceutical Sciences and Research, 13(3), 1099–1107.
  26. [26] Fadilah, N. A., & Syahputra, R. (2025). Studi molekuler docking potensi senyawa tumbuhan kalangkala (Litsea angulata) sebagai antihiperpigmentasi. Jurnal Bina Cipta Husada: Jurnal Kesehatan dan Science, 21(2), 80–86.
  27. [27] Angelova, M., Alov, P., Tsakovska, I., Jereva, D., Lessigiarska, I., Atanassov, K., Pajeva, I., & Pencheva, T. (2025). Pairwise performance comparison of docking scoring functions: Computational approach using intercriteria analysis. Molecules, 30.
  28. [28] Alhumaid, N., & Tawfik, E. (2024). Reliability of AlphaFold2 models in virtual drug screening: A focus on selected class A GPCRs. International Journal of Molecular Sciences, 25.
  29. [29] Tripathi, A., Suri, K., K., S., & Murugan, N. (2025). Assessing the accuracy of binding pose prediction for kinase proteins and 7-azaindole inhibitors: A study with AutoDock4, Vina, DOCK 6, and GNINA 1.0. RSC Advances, 15, 47051–47065.
  30. [30] Abdullahi, M., Uzairu, A., Adamu, G., Andrew, P., & Tukur, M. (2023). Computational modelling of some phenolic diterpenoid compounds as anti-influenza A virus agents. Scientific African, 19, Article e01462.
  31. [31] Singh, A. V., et al. (2023). Coronavirus-mimicking nanoparticles (CorNPs) in artificial saliva droplets and nanoaerosols: Influence of shape and environmental factors on particokinetics/particle aerodynamics. Science of the Total Environment, 860, Article 160503.
  32. [32] Caminero Gomes Soares, A., Marques Sousa, G. H., Calil, R. L., & Goulart Trossini, G. H. (2023). Absorption matters: A closer look at popular oral bioavailability rules for drug approvals. Molecular Informatics, 42(11), e202300115.
  33. [33] Sardar, H. (2023). Drug like potential of daidzein using SwissADME prediction: In silico approaches. Phytonutrients, 2–8.
  34. [34] Mardianingrum, R., Bachtiar, K. R., Susanti, S., Aas Nuraisah, A. N., & Ruswanto, R. (2021). Studi in silico senyawa 1,4-naphthalenedione-2-ethyl-3-hydroxy sebagai antiinflamasi dan antikanker payudara. Alchemy Jurnal Penelitian Kimia, 17(1), 83.
  35. [35] Jadar, P. G., & Haritha, M. M. (2025). Evaluation of phytochemicals from Azadirachta indica for drug-like properties: A computational insight into natural product-based drug discovery. Journal of Ayurveda and Holistic Medicine, 13(8), 63–78.
  36. [36] Kibet, S., Kimani, N. M., Mwanza, S. S., Mudalungu, C. M., Santos, C. B., & Tanga, C. M. (2024). Unveiling the potential of ent-kaurane diterpenoids: Multifaceted natural products for drug discovery. Pharmaceuticals, 17(4), 510.
  37. [37] Muhammad, M., Uzairu, A., Abechi, S. E., & Ibrahim, M. T. (2026). In silico design of some potent antioxidant compounds using 2D-QSAR, molecular docking and ADMET studies. Current Pharmaceutical Analysis.
  38. [38] Flores-Holguín, N., Frau, J., & Glossman-Mitnik, D. (2021). Computational pharmacokinetics report, ADMET study and conceptual DFT-based estimation of the chemical reactivity properties of marine cyclopeptides. ChemistryOpen, 10(11), 1142–1149.
  39. [39] Utami, D., Syahputra, R., & Widyaningsih, W. (2022). Studi docking molekular aktivitas penghambatan enzim tirosinase ubi jalar (Ipomoea batatas L. Lam). Pharmacon: Jurnal Farmasi Indonesia, 19(1), 21–34. https://doi.org/10.23917/pharmacon.v19i1.18295
  40. [40] Chunduri, V., & Maddi, S. (2023). Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: A comprehensive review. ADMET and DMPK, 11(1), 1–32.
  41. [41] Poli, A., Agostoni, C., & Visioli, F. (2023). Dietary fatty acids and inflammation: Focus on the n-6 series. International Journal of Molecular Sciences, 24(5), 4567.
  42. [42] Mendes de Oliveira, E., Silva, J. C., Ascar, T. P., Sandri, S., Marchi, A. F., Migliorini, S., ... & Campa, A. (2022). Acute inflammation is a predisposing factor for weight gain and insulin resistance. Pharmaceutics, 14(3), 623.
  43. [43] Iwata, H., et al. (2022). Predicting total drug clearance and volumes of distribution using the machine learning-mediated multimodal method through the imputation of various nonclinical data.
  44. [44] Liu, S., & Shah, D. K. (2022). Mathematical models to characterize the absorption, distribution, metabolism, and excretion of protein therapeutics. Drug Metabolism and Disposition, 50(6), 867–878.
  45. [45] Deng, C., Liu, J., & Zhang, W. (2022). Structural modification in anesthetic drug development for prodrugs and soft drugs. Frontiers in Pharmacology, 13, 1–14.
  46. [46] Lai, Y., Yanev, S., & Liu, Z. (2023). Editorial: Clinical trials in drug metabolism and transport: 2022. Frontiers in Pharmacology, 13–15.
  47. [47] Semyachkina-Glushkovskaya, O., Bragin, D., Bragina, O., Socolovski, S., Shirokov, A., Fedosov, I., ... & Rafailov, E. (2023). Low-level laser treatment induces the blood-brain barrier opening and the brain drainage system activation: Delivery of liposomes into mouse glioblastoma. Pharmaceutics, 15(2), 567.
  48. [48] Wu, K. Y., Ahmad, H., Lin, G., Carbonneau, M., & Tran, S. D. (2023). Mesenchymal stem cell-derived exosomes in ophthalmology: A comprehensive review. Pharmaceutics, 15(4), 1167.
  49. [49] Ungureanu, D., Tiperciuc, B., Nastasă, C., Ionuț, I., Marc, G., Oniga, I., & Oniga, O. (2024). An overview of the structure–activity relationship in novel antimicrobial thiazoles clubbed with various heterocycles (2017–2023). Pharmaceutics, 16(1), 89.
  50. [50] Odhiambo, D. O., Omosa, L. K., Njagi, E. C., Kithure, J. G., & Wekesa, E. N. (2025). In-silico pharmacokinetics ADME/Tox analysis of phytochemicals from genus Dracaena for their therapeutic potential. Scientific African, 29, Article e02796.
  51. [51] Abdelwahab, A. A., Elattar, M. A., & Fawzi, S. A. (2025). Advancing ADMET prediction for major CYP450 isoforms: Graph-based models, limitations, and future directions. BioMedical Engineering OnLine, 24(1), 93.
  52. [52] Zhai, J., Man, V. H., Ji, B., Cai, L., & Wang, J. (2024). Comparison and summary of in silico prediction tools for CYP450-mediated drug metabolism. Drug Discovery Today, 28(10), 1–29.
  53. [53] Lee, H., Kim, J., Kim, J., & Lee, Y. (2025). Recent advances in AI-based toxicity prediction for drug discovery. Frontiers in Chemistry, 1–19.
  54. [54] Mostafa, F., Howle, V., & Chen, M. (2024). Machine learning to predict drug-induced liver injury and its validation on failed drug candidates in development. Toxics, 12(6), 385.
  55. [55] Ryu, J. Y., Jang, W. D., Jang, J., & Oh, K. S. (2023). PredAOT: A computational framework for prediction of acute oral toxicity based on multiple random forest models. BMC Bioinformatics, 1–10.

Most read articles by the same author(s)